阿来替尼靶向疗法联合吉西他滨化疗对肺腺癌患者肺功能、Ki-67、CEA的影响  

Effects of Aliteinib Combined with Gemcitabine Chemotherapy on Lung Function,Ki-67 and CEA in Patients with Lung Adenocarcinoma

作　　者：朱梦楚 黄晓颖[2] ZHU Meng-chu;HUANG Xiao-ying(Department of Respiratory Medicine,the No.3 Affiliated Hospital of Wenzhou Medical University,Wenzhou 325000,China;Department of Respiratory Medicine,the No.1 Affiliated Hospital of Wenzhou Medical University,Wenzhou 325000,China)

机构地区：[1]温州医科大学附属第三医院呼吸内科,浙江温州325000 [2]温州医科大学附属第一医院呼吸内科,浙江温州325000

出　　处：《药物生物技术》2021年第5期496-500,共5页Pharmaceutical Biotechnology

基　　金：温州市科技局项目(No.Y20180596)。

摘　　要：探讨阿来替尼靶向疗法联合吉西他滨化疗治疗肺腺癌的临床疗效,分析其对患者肺功能、Ki-67、CEA的影响。选择2019年5月至2020年5月温州医科大学附属第三和第一医院肿瘤内科收治的肺腺癌患者118例作为研究对象,依据随机数表法分为研究组、对照组,各59例。对照组患者接受吉西他滨化疗,研究组患者给予阿来替尼靶向疗法联合吉西他滨化疗治疗。对比两组患者的临床疗效,肺功能指标、肿瘤组织Ki-67、CEA表达及不良反应情况。研究组患者的治疗中有效率96.61%(57/59),高于对照组76.27%(45/59)(P<0.05);两组患者治疗后FEV1、FVC、FEV1/FVC指标水平均明显提升,且研究组均高于对照组(P<0.05);治疗后,研究组患者肿瘤组织Ki-67阳性表达率37.29%(22/59),低于对照组的66.10%(39/59)(P<0.05);两组患者治疗后血清CEA表达水平均低于治疗前,且研究组低于对照组(P<0.05);研究组患者治疗后骨髓抑制、疲乏等不良反应发生率均明显低于对照组(P<0.05)。阿来替尼联合吉西他滨治疗肺腺癌的疗效确切,可有效改善肺腺癌患者的肺功能指标,降低肿瘤Ki-67、CEA表达,减少不良反应风险。To explore the clinical efficacy of alectinib targeted therapy combined with gemcitabine chemotherapy in the treatment of lung adenocarcinoma,and to analyze the effects on lung function,Ki-67,and CEA of patients,118 cases of patients with lung adenocarcinoma admitted to the authors’hospital’s medical oncology from May 2019 to May 2020 were selected as the subjects of this study.All patients in the study group and control group based on the random number table method,59 cases in each group.The patients in the control group were given gemcitabine chemotherapy,and the patients in the study group had received aliteinib targeted therapy in combination with gemcitabine chemotherapy.The clinical efficacy,lung function indexes,Ki-67 and CEA expression of tumor tissues and adverse reactions were compared between the two groups.The effective rate of treatment group patients was96.61%(57/59)higher than the control group 76.27%(45/59)(P<0.05).After treatment,the FEV1,FVC,and FEV1/FVC indicators of the two groups were significantly improved,and the study group was higher than those in the control group(P<0.05).The positive expression rate of Ki-67 in the tumor tissue of the study group was 37.29%(22/59),which was lower than that in the control group(66.10%,39/59)(P<0.05).The serum CEA expression level of the two groups of patients after treatment was lower than before treartment,and the study group was lower than that in the control group(P<0.05).The incidence of adverse reactions such as bone marrow suppression and fatigue in the study group was significantly lower than that in the control group(P<0.05).Alectinib combined with gemcitabine has a definite curative effect on lung adenocarcinoma.It could effectively improve the lung function indexes of patients with lung adenocarcinoma,reduce the expression of Ki-67 and CEA in tumor tissues,and reduce the risk of adverse reactions.It was worthy of clinical application and promotion.

关 键 词：阿来替尼 吉西他滨 肺腺癌 化疗 肺功能 癌胚抗原 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]